Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor

Abstract

Acute coronary syndromes (ACS) are the leading cause of mortality in Western countries. Until a few years ago, the antiplatelet drug to be administered in association with aspirin was indisputably clopidogrel. Recent data from randomized trials conducted in ACS patients have shown that the new oral antiplatelet regimens, prasugrel and ticagrelor, are associated with a significant reduction in cardiovascular events, as compared to clopidogrel. Moreover ticagrelor reduced both all-cause and cardiovascular mortality as compared to clopidogrel in the PLATO trial. However, there are intrinsic differences between the trials design and among the enrolled ACS populations, that make complex the generalization of the mortality results in the whole spectrum of ACS patients. We aimed to provide further insights into the unresolved mortality issues raised in the PLATO and TRITON–TIMI 38 trials, by analysing the effects of ticagrelor and prasugrel in the ACS populations included in the respective trials.

Key words::

• Acute coronary syndromes
• Mortality
• New antiplatelet drugs
• Randomized studies

Transparency

Declaration of funding

This editorial was not sponsored.

Declaration of financial/other relationships

The authors have received no payment in preparation of this manuscript. EPN and MDU have disclosed that they have no relevant financial relationships. SDS has received speaker's fees as well as fees for Advisory Boards activities from Eli-Lilly and Astra-Zeneca. SS has received speaker's fees as well as fees for Advisory Boards activities from Eli-Lilly.

The peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.